Liljedahl, Emelie Rietz https://orcid.org/0000-0001-8742-5383
Engfeldt, Malin
Nielsen, Kari
Jöud, Anna
Nielsen, Christel
Funding for this research was provided by:
Lund University
Article History
Received: 14 October 2024
Accepted: 2 April 2025
First Online: 25 April 2025
Declarations
:
: The study was conducted according to the guidelines of the Declaration of Helsinki, and was approved by the Swedish Ethical Review Authority (2019–03138, date of approval 2019-06-05).
: Informed consent was obtained from all subjects involved in the study.
: The work was supported by research funding to CN from the Swedish Research Council for Health, Working Life and Welfare, The Crafoord Foundation, and Magnus Bergvalls Foundation, to KN from the Southern health care region, Sweden, the S.R. Gorthon foundation, the Welander Finsen foundation (Hudfonden), the LMK foundation, grants from the Swedish state under the agreement between the Swedish government and the county councils (the ALF agreement), the Inga and John Hain Foundation for medical research, and the Gyllenstiernska Krapperup Foundation. KN has received speaker honoraria from Galderma Sweden, LEO Pharma Sweden, Novartis Sweden and UCB Pharma Sweden. KN has 2021 served on one advisory board for Merck Sharp and Dohme (MSD), and finally KN is President of the Board for the National Melanoma Guidelines and President for the Swedish Society of Dermatological Surgery and Oncology. The authors declare no other relationships or activities that could appear to have influenced the submitted work.